Table 1

Baseline Characteristics of All Patients in Sweden From 2009 to 2013 With a First MI in Relation to the Troponin Assay Used for Diagnosis

All Patients (N = 87,879) (100%)cTn (n = 47,133) (54%)hs-cTnT (n = 40,746) (46%)
Age, yrs73.2 ± 13.073.7 ± 13.072.7 ± 13.0
Men52,682 (60)27,845 (59)24,837 (61)
Prior stroke9,792 (11)5,510 (12)4,282 (11)
COPD5,385 (6)2,882 (6)2,503 (6)
Prior heart failure9,025 (10)5,148 (11)3,877 (10)
Diabetes14,191 (16)7,597 (16)6,594 (16)
Chronic kidney disease2,466 (3)1,292 (3)1,174 (3)
Prior coronary angiography3,661 (4)1,713 (4)1,948 (5)
Revascularization4,998 (6)2,560 (5)2,438 (6)
Aspirin27,192 (31)14,932 (32)12,260 (30)
P2Y12 inhibitors1,882 (2)925 (2)957 (2)
Beta-blockers29,756 (34)16,354 (35)13,402 (33)
ACE inhibitor/ARB30,759 (35)16,345 (35)14,414 (35)
Statins19,142 (22)10,029 (21)9,113 (22)

Values are mean ± SD or n (%).

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; COPD = chronic obstructive pulmonary disease; cTn = conventional cardiac troponin; hs-cTnT = high-sensitivity cardiac troponin T; MI = myocardial infarction.

  • Does not include patients who were diagnosed at 9 hospitals that used the hs-cTnT assay during a limited time period, but with a higher decision limit for MI than the 99th percentile value. In addition, it includes a few cases that were diagnosed in health care settings other than acute care hospitals. These cases are shown in Table 2.

  • P2Y12 inhibitors includes clopidogrel, ticagrelor, and prasugrel.